Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Holdings Decreased by Pendal Group Ltd
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Holdings Decreased by Pendal Group Ltd
Shares of MRVI stock opened at $13.50 on Friday. The stock has a 50-day simple moving average of $14.54 and a 200 day simple moving average of $16.00. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $12.16 and a fifty-two week high of $38.79. The stock has a market capitalization of $3.45 billion, a P/E ratio of 8.18 and a beta of -0.22. The company has a quick ratio of 7.31, a current ratio of 7.70 and a debt-to-equity ratio of 0.58. Pendal Group Ltd trimmed its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) by 31.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,543 shares of the company's stock after selling 6,241 shares during the quarter. Pendal Group Ltd's holdings in Maravai LifeSciences were worth $194,000 as of its most recent filing with the Securities and Exchange Commission.
彭達集團有限公司根據最近 13F 向證券交易委員會提交的文件，在第四季度將其在馬拉瓦生命控股公司（NASDAQ：MRVI-獲得評級）的位置下調了 31.5％。該基金在本季度賣出 6,241 股股票後，擁有該公司股票的 13,543 股。彭達集團有限公司最近向證券交易委員會提交的申報價值為 194,000 美元。
A number of other institutional investors have also made changes to their positions in the company. Zions Bancorporation N.A. acquired a new position in Maravai LifeSciences during the 1st quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. acquired a new position in Maravai LifeSciences during the 3rd quarter valued at approximately $31,000. Signaturefd LLC boosted its position in Maravai LifeSciences by 200.5% during the 3rd quarter. Signaturefd LLC now owns 1,202 shares of the company's stock valued at $31,000 after purchasing an additional 802 shares during the period. PenderFund Capital Management Ltd. acquired a new position in Maravai LifeSciences during the 2nd quarter valued at approximately $44,000. Finally, Van ECK Associates Corp boosted its position in Maravai LifeSciences by 56.7% during the 3rd quarter. Van ECK Associates Corp now owns 4,480 shares of the company's stock valued at $114,000 after purchasing an additional 1,621 shares during the period. 48.67% of the stock is currently owned by institutional investors.
一些其他機構投資者也對其在公司的頭寸進行了更改。ZION 銀行公司 N.A. 在第一季度收購了馬拉瓦生命醫學中的新職位，價值約為 28,000 美元。中國環球資產管理有限公司Ltd. 在第三季度收購了馬拉瓦生命中心的新職位，價值約為 31,000 美元。簽署有限責任公司在第三季度將其在馬拉瓦伊生命中的地位提高了 200.5％。在此期間額外購買 802 股股票後，簽署有限責任公司現在擁有該公司股票的 1,202 股價值 31,000 美元。彭德基金資本管理有限公司在第二季度收購了馬拉瓦生命中心的新職位，價值約為 44,000 美元。最後, 凡埃克聯營公司提高了其在馬拉瓦生命中的地位 56.7% 在第三季度.範 ECK 聯營公司現在擁有該公司股票 4,480 股，價值為 114,000 美元，在此期間內額外購買 1,621 股。48.67％ 的股票目前由機構投資者擁有。
Analyst Ratings Changes
分析師等級變更
A number of research analysts recently issued reports on MRVI shares. UBS Group lowered Maravai LifeSciences from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $20.00 to $16.00 in a research report on Thursday, January 5th. Royal Bank of Canada assumed coverage on Maravai LifeSciences in a research note on Tuesday, December 6th. They issued an "outperform" rating and a $22.00 price target for the company. Credit Suisse Group decreased their price target on Maravai LifeSciences from $26.00 to $23.00 and set an "outperform" rating for the company in a research note on Thursday, February 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on Maravai LifeSciences in a research note on Tuesday, December 13th. They issued a "buy" rating and a $25.00 price target for the company. Finally, KeyCorp decreased their price target on Maravai LifeSciences from $28.00 to $24.00 and set an "overweight" rating for the company in a research note on Thursday, February 23rd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Maravai LifeSciences presently has an average rating of "Moderate Buy" and a consensus price target of $21.56.
一些研究分析師最近發表了有關 MRVI 股份的報告。瑞銀集團在 1 月 5 日（星期四）的一份研究報告中，將 Maravai LifeCences 從「買入」評級下調至「中立」評級，並將公司的價格目標從 20.00 美元降至 16.00 美元。加拿大皇家銀行在 12 月 6 日（星期二）的一份研究筆記中承擔了馬拉瓦伊生命科技的報導。他們為該公司發布了「跑贏大市」評級和 22.00 美元的目標價格。瑞士信貸集團將馬拉瓦生活的目標價格從 26.00 美元降至 23.00 美元，並在 2 月 23 日（星期四）的研究報告中為該公司設定了「跑贏大市」評級。德意志銀行股份有限公司在 12 月 13 日（星期二）的一份研究報告中承擔了馬拉瓦伊生命科技的報導。他們為該公司發布了「買入」評級和 25.00 美元的目標價格。最後，KeyCorp 將其在馬拉瓦生活中的目標價格從 28.00 美元降至 24.00 美元，並在 2 月 23 日（星期四）的研究報告中為該公司設置了「超重」評級。兩位分析師對該股票進行了保持評級，七位分析師對該股票進行了買入評級。根據 MarketBeat.com 的數據，馬拉瓦生活目前的平均評級為「適度買入」，共識價格目標為 21.56 美元。
Maravai LifeSciences Trading Down 1.0 %
馬拉瓦生命週期交易下降 1.0%
Shares of MRVI stock opened at $13.50 on Friday. The stock has a 50-day simple moving average of $14.54 and a 200 day simple moving average of $16.00. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $12.16 and a fifty-two week high of $38.79. The stock has a market capitalization of $3.45 billion, a P/E ratio of 8.18 and a beta of -0.22. The company has a quick ratio of 7.31, a current ratio of 7.70 and a debt-to-equity ratio of 0.58.
上週五，MRVI 股票開盤價為 13.50 美元。該股有一個 50 天的簡單移動平均線 14.54 美元和 200 天的簡單移動平均線 16.00 美元。馬拉瓦生命控股有限公司擁有五十二周低點 12.16 美元，創下五十二周高點 38.79 美元。該股的市值為 345 億美元，市盈率為 8.18，貝塔值為 -0.22。該公司的快速比率為 7.31，流動比率為 7.70，債務與權益比率為 0.58。
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last announced its earnings results on Wednesday, February 22nd. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.34 by $0.01. Maravai LifeSciences had a return on equity of 57.88% and a net margin of 24.94%. The business had revenue of $204.70 million during the quarter, compared to the consensus estimate of $204.95 million. During the same period in the prior year, the business posted $0.45 earnings per share. Maravai LifeSciences's revenue was down 10.4% compared to the same quarter last year. On average, sell-side analysts expect that Maravai LifeSciences Holdings, Inc. will post 0.35 earnings per share for the current fiscal year.
馬拉瓦生命 (納斯達克:MRVI — 獲得評分) 最後公佈其收益結果週三, 2 月 22 日.該公司報告了本季每股收益 0.35 美元，超過 0.34 美元的共識估計值 0.01 美元。馬拉瓦生命保護的股本回報率為 57.88%，淨利潤率為 24.94％。該業務在本季度的收入為 20,470 萬美元，而共識估計為 204.95 億美元。在上一年同期，該業務公佈了每股 0.45 美元的盈利。與去年同期相比，馬拉瓦生命科技的收入下降了 10.4%。平均而言，賣方分析師預計，馬拉瓦生命科技控股有限公司將在本財政年度公佈每股 0.35 收益。
About Maravai LifeSciences
關於馬拉瓦生命
(Get Rating)
(取得評分)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Maravai Lifesciences 控股有限公司是一家生命科學公司，提供產品以促進藥物療法、診斷、新型疫苗的開發，並支援美國和國際上對人類疾病的研究。該公司的產品解決了生物製藥開發的關鍵階段，包括用於診斷和治療應用的核酸，生物製藥產品生產過程中檢測雜質的抗體產品以及檢測各種組織中蛋白質表達的產品。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Maravai LifeSciences (MRVI)
- The Squeeze Is On For EVGo, Rally To Follow
- Is The Bottom In For RH, Or Is This Just A Stopping Point?
- Dividend King H.B. Fuller Signals Slowing In 2023
- Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
- 3 Companies That Just Started Paying Dividends
- 免費獲取有關馬拉瓦伊生命研究（MRVI）的研究報告
- eVGo 的擠壓正在進行，集會跟隨
- 是 RH 的底部，還是這只是一個停止點？
- 股息國王 H.B 富勒信號在 2023 年放緩
- SoFi 技術在銀行危機中是否可以購買？
- 3 家剛開始支付股息的公司
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收馬拉瓦伊生命日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Maravai Lifesciences 和相關公司的最新新聞和分析師評級的簡要每日摘要。
